INS and diabetes mellitus: In a multivariate regression model, treatment with liraglutide (adjusted for potential confounders including BMI, duration of diabetes, insulin use, duration of lipid-lowering treatment, triglyceride levels, and Hb1Ac) was not associated with a change in TAV (β 39.0, 95% CI -16.7 ; 94 − 7, P = 0.17).